Concepedia

Publication | Open Access

Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis

DOIFull Paper Access

39

Citations

16

References

2021

Year

Rifaat Safadi, Marius Braun, Adi Francis, Yael Milgrom, Muhammad Massarwa, David Hakimian, Wadi Hazou, Assaf Issachar, Zivit Harpaz, Motti Farbstein,
Alimentary Pharmacology & Therapeutics

Abstract

A3AR is a valid target; namodenoson 25 mg b.d. was safe and demonstrated efficacy signals (ClinicalTrials.gov #NCT02927314).

References

YearCitations

Page 1